BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Westen E, Knol MJ, Wijmenga-Monsuur AJ, Tcherniaeva I, Schouls LM, Sanders EAM, van Els CACM, Berbers GAM, Rots NY. Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine. Vaccines (Basel) 2018;6:E82. [PMID: 30544898 DOI: 10.3390/vaccines6040082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kaur R, Pichichero M. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine. Vaccine 2020;38:4423-31. [PMID: 32402752 DOI: 10.1016/j.vaccine.2020.04.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 de Koff EM, van Houten MA, de Heij F, Berbers GAM, Bogaert D, Sanders EAM. Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort. Vaccine 2021:S0264-410X(21)01622-4. [PMID: 34961634 DOI: 10.1016/j.vaccine.2021.12.013] [Reference Citation Analysis]
3 Licciardi P, Papadatou I. Pneumococcal Vaccines: Challenges and Prospects. Vaccines (Basel) 2019;7:E25. [PMID: 30818791 DOI: 10.3390/vaccines7010025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Uffman EA, Li SH, Chen JL, Allen N, Boiditswe S, Fouda GG, Hurst JH, Patel MZ, Steenhoff AP, Cunningham CK, Qin E, Davenport CA, Kelly MS. Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana. Vaccine 2022:S0264-410X(22)00828-3. [PMID: 35773120 DOI: 10.1016/j.vaccine.2022.06.059] [Reference Citation Analysis]
5 Mokaddas E, Syed S, Albert MJ. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019. Hum Vaccin Immunother 2021;:1-6. [PMID: 34435932 DOI: 10.1080/21645515.2021.1968216] [Reference Citation Analysis]
6 Hong E, Terrade A, Denizon M, Aouiti-Trabelsi M, Falguières M, Taha MK, Deghmane AE. Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules. BMC Infect Dis 2021;21:715. [PMID: 34330228 DOI: 10.1186/s12879-021-06440-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rouers EDM, Bruijning-Verhagen PCJ, van Gageldonk PGM, van Dongen JAP, Sanders EAM, Berbers GAM. Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants. JAMA 2020;324:1068-77. [PMID: 32930758 DOI: 10.1001/jama.2020.12316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Morton B, Jambo K, Chikaonda T, Rylance J, Henrion MY, Banda NP, Nsomba E, Gondwe J, Ferreira D, Gordon SB; MARVELS Consortium. The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol. Wellcome Open Res 2021;6:240. [DOI: 10.12688/wellcomeopenres.17172.2] [Reference Citation Analysis]